Abstract Library

#2970 Characteristics, Treatments and Inflammatory Biomarkers in Patients (pts) with G3 Gastroenteropancreatic (GEP) Neuroendocrine Neoplasms (NENs)

Introduction: Well-differentiated neuroendocrine tumors G3 (NETsG3) pts have a different biological behavior compared to those with neuroendocrine carcinomas (NECs). Sensitivity to platinum depends on Ki67 and there is no standard second line (2L). Neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) are predictive factors of cancer survival, but with limited evidence in NENs.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Cameselle-Garcia S, Sardo E, Landolfi S, Merino-Casabiel X, Sánchez J,

Keywords: Neuroendocrine Neoplasms, Inflammatory Biomarkers, Gastroenteropancreatic,

#2749 Impact of Next-Generation Sequencing Analyses on Treatment Management of Patients with Advanced Neuroendocrine Neoplasms

Introduction: Molecular genomic analyses are widely used in oncology but experience in advanced neuroendocrine neoplasms (NENs) is still limited.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Garcia Alvarez A

Authors: Garcia-Alvarez A, Hernando J, Vivancos A, Landolfi S, Casteras A,

Keywords: NGS, BRAF, RET,

#2180 BRAF-V600E Driven Mutations in Grade 3 Neuroendocrine Carcinomas of Colon Origin: Results from Genomic/Epigenomic Profilings and Patient-Derived Mouse Model

Introduction: NECs of colon origin are orphan and highly aggressive neoplasms with limited molecular knowledge.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Capdevila J

Authors: Capdevila J, Mancuso F, Landolfi S, Martinez-Cardus A, Barriuso J,

Keywords: Neuroendocrine carcinoma, Genomics, Epigenomics, BRAFV600E, Patient-derived xenograft,

#445 Comparison of Prognostic Capacity for Overall Survival (OS) and Disease-Free Survival (DFS) of Neuroendocrine Tumors (NETs) Classifications: 2010 WHO, TNM Staging-ENETS and AJCC

Introduction: Current NETs classifications are: WHO, ENETS and AJCC. No consensus exists about which one more accurately predicts NET outcomes.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Mulet-Margalef N, Landolfi S, Sánchez-Ollé G, Argilés G, Balsells J,

Keywords: net, ENETS, AJCC, WHO, overall survival, disease free survival,

#79 PTOV-1 overexpression in neuroendocrine tumors: a new molecular marker

Introduction: PTOV-1 (Prostate Tumor Overexpressed-1) is a novel protein encoded by 12-exon gene localized in chromosome 19q.13.3. Recently identified as an androgen-induced gene, it is involved in prostate cell proliferation and in prostate human cancer. PTOV-1 expression has been demonstrated in neuroendocrine cells of normal prostate tissue. Preliminary data indicate that PTOV-1 can be related to flotilin, integrins and other cellular factors involved in cancer progression.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author: Landolfi S

Authors: de Torres I, Castellvi J, Landolfi S, Fernandez S, Alaña L,

Keywords: PTOV-1, chromogranin A, NETs, inmunohistochemistry,